Close

BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

Go back to BioMarin (BMRN) PT Raised to $120 at Piper Jaffray

BioMarin Announces Second Quarter 2016 Financial Results

August 4, 2016 4:03 PM EDT

- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million

- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $340 to $360 million

- Kuvan Net Product Revenue Contributes $90.2 million in the Second Quarter 2016; Kuvan Full-year Revenue Guidance Increased to $340 to $360 million

- Strong Kuvan and Vimizim Results Drive Increased FY 2016 Top-line Guidance to $1.10 billion - $1.15 billion

Financial Highlights (in millions of U.S. dollars, except per share data,... More